Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above 200-Day Moving Average – Here’s Why

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.62 and traded as high as $6.61. Cumberland Pharmaceuticals shares last traded at $5.77, with a volume of 318,162 shares trading hands.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on CPIX shares. Wall Street Zen lowered Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Cumberland Pharmaceuticals presently has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Price Performance

The firm has a market capitalization of $86.43 million, a P/E ratio of -11.78 and a beta of -0.06. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.95 and a quick ratio of 0.79. The stock’s fifty day simple moving average is $3.86 and its 200 day simple moving average is $3.62.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, hitting analysts’ consensus estimates of ($0.13). The business had revenue of $9.13 million during the quarter, compared to the consensus estimate of $8.50 million. Cumberland Pharmaceuticals had a negative net margin of 17.60% and a negative return on equity of 12.01%.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new position in Cumberland Pharmaceuticals in the second quarter worth about $34,000. Arrowstreet Capital Limited Partnership bought a new position in Cumberland Pharmaceuticals in the first quarter worth about $66,000. Two Sigma Investments LP raised its holdings in Cumberland Pharmaceuticals by 16.5% in the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after purchasing an additional 5,326 shares in the last quarter. Marshall Wace LLP bought a new position in Cumberland Pharmaceuticals in the fourth quarter worth about $192,000. Finally, Geode Capital Management LLC raised its holdings in Cumberland Pharmaceuticals by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock worth $427,000 after purchasing an additional 5,653 shares in the last quarter. 15.51% of the stock is currently owned by institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.